Bjørk, Emma http://orcid.org/0000-0001-6794-1479
Aabenhus, Rune http://orcid.org/0000-0001-9354-2236
Larsen, Søren P. http://orcid.org/0009-0000-8854-1909
Ryg, Jesper http://orcid.org/0000-0002-8641-3062
Henriksen, Daniel P. http://orcid.org/0000-0003-1303-6195
Lundby, Carina http://orcid.org/0000-0002-2121-6252
Pottegård, Anton http://orcid.org/0000-0001-9314-5679
Funding for this research was provided by:
Danmarks Frie Forskningsfond (2034-00305B)
University of Southern Denmark
Article History
Received: 28 August 2023
Accepted: 1 April 2024
First Online: 2 May 2024
Declarations
:
: Anton Pottegård reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma, all regulator-mandated phase IV-studies, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. Remaining authors report no conflict of interest.
: This study was conducted in accordance with the Declaration of Helsinki. This study did not require approval from an ethics review board, according to Danish law on studies based solely on register data. In terms of data protection, the study was registered at the repository of University of Southern Denmark (11.277).
: For this type of study, relying solely on registries not using biological material, no informed consent is required.